[go: up one dir, main page]

EP1013285A3 - Urokinase-type plasminogen activator receptor - Google Patents

Urokinase-type plasminogen activator receptor Download PDF

Info

Publication number
EP1013285A3
EP1013285A3 EP00104681A EP00104681A EP1013285A3 EP 1013285 A3 EP1013285 A3 EP 1013285A3 EP 00104681 A EP00104681 A EP 00104681A EP 00104681 A EP00104681 A EP 00104681A EP 1013285 A3 EP1013285 A3 EP 1013285A3
Authority
EP
European Patent Office
Prior art keywords
preventing
urokinase
plasminogen activator
type plasminogen
activator receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00104681A
Other languages
German (de)
French (fr)
Other versions
EP1013285A2 (en
Inventor
Keld Dano
Francesco Blasi
Ann Louring Roldan
Maria Vittoria Dip. Chem Org. e Bio Cubellis
Maria Teresa c/o Exper. Oncology Dept B Masucci
Ettore c/o Lab. for Cell Biology Appella
Wolf Dieter Schleuning
Niels Behrendt
Ebbe Roenne
Peter Kristesen
Jari PÖLLÄNEN
Eeva-Marjatte c/o Dept of Virology Salonen
Ross W. Stephens
Hannele c/o Dept. of Virology Tapiovaara
Antti c/o Dept of Virology Vaheri
Lisbeth Birk Moeller
Vincent Ellis
Leif Roege Lund
Michael Ploug
Charles Pyke
Lászlo c/o Institute of Enzmology Patthy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancerforskningsfonden af 1989 (fonden til fremme af eksperimentel cancerforskning)
Cancerforskningsfondet af 1989
Original Assignee
Cancerforskningsfonden af 1989 (fonden til fremme af eksperimentel cancerforskning)
Cancerforskningsfondet af 1989
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancerforskningsfonden af 1989 (fonden til fremme af eksperimentel cancerforskning), Cancerforskningsfondet af 1989 filed Critical Cancerforskningsfonden af 1989 (fonden til fremme af eksperimentel cancerforskning)
Publication of EP1013285A2 publication Critical patent/EP1013285A2/en
Publication of EP1013285A3 publication Critical patent/EP1013285A3/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6462—Plasminogen activators u-Plasminogen activator (3.4.21.73), i.e. urokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21073—Serine endopeptidases (3.4.21) u-Plasminogen activator (3.4.21.73), i.e. urokinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57446—Specifically defined cancers of stomach or intestine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/972—Plasminogen activators
    • G01N2333/9723—Urokinase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)

Abstract

The use of substances capable of preventing the binding of a receptor binding form of u-PA to a u-PA receptor (u-PAR) in a mammal and thereby preventing u-PA from converting plasminogen into plasmin thereby preventing cell surface plasminogen activation which is believed to play an important role in tissue remodelling, particularly during cancer invasion for preparing a composition for preventing or counteracting localized proteolytic activity in a mammal, in particular a human.
EP00104681A 1989-04-07 1990-04-09 Urokinase-type plasminogen activator receptor Withdrawn EP1013285A3 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US33461389A 1989-04-07 1989-04-07
US334613 1989-04-07
US37485489A 1989-07-03 1989-07-03
US374854 1989-07-03
EP90906148A EP0467932B1 (en) 1989-04-07 1990-04-09 Urokinase-type plasminogen activator receptor

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
EP90906148A Division EP0467932B1 (en) 1989-04-07 1990-04-09 Urokinase-type plasminogen activator receptor
EP90906148.3 Division 1990-10-23

Publications (2)

Publication Number Publication Date
EP1013285A2 EP1013285A2 (en) 2000-06-28
EP1013285A3 true EP1013285A3 (en) 2004-05-19

Family

ID=26989284

Family Applications (2)

Application Number Title Priority Date Filing Date
EP90906148A Expired - Lifetime EP0467932B1 (en) 1989-04-07 1990-04-09 Urokinase-type plasminogen activator receptor
EP00104681A Withdrawn EP1013285A3 (en) 1989-04-07 1990-04-09 Urokinase-type plasminogen activator receptor

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP90906148A Expired - Lifetime EP0467932B1 (en) 1989-04-07 1990-04-09 Urokinase-type plasminogen activator receptor

Country Status (9)

Country Link
US (1) US6248712B1 (en)
EP (2) EP0467932B1 (en)
JP (2) JPH04506148A (en)
AT (1) ATE197067T1 (en)
AU (2) AU652917B2 (en)
CA (1) CA2051676A1 (en)
DE (2) DE467932T1 (en)
DK (1) DK0467932T3 (en)
WO (1) WO1990012091A1 (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2246779B (en) * 1990-08-03 1994-08-17 Delta Biotechnology Ltd Tumour-associated protease inhibitors targeted to tumour cells
EP1281404A3 (en) * 1990-10-18 2004-04-07 Cancerforskningsfonden af 1989 (fonden til fremme af eksperimentel cancerforskning) Use of antibodies against the urokinase receptor
GB9026737D0 (en) * 1990-12-08 1991-01-30 Delta Biotechnology Ltd Cancer treatment
ES2143504T3 (en) * 1992-05-28 2000-05-16 Univ Toledo USE OF A CYTOTOXIC MATERIAL COUPLED WITH A PLASMINOGEN ACTIVATOR INHIBITING MATERIAL FOR THE PRODUCTION OF A MEDICINE FOR THE TREATMENT OF CANCER CELLS.
US5679350A (en) * 1992-05-28 1997-10-21 The University Of Toledo Method of delivery of a medicament to a cancer cell using a pathway of plasminogen activator material
JP2852192B2 (en) 1994-07-08 1999-01-27 カンセアフォースクニングスフォンデン・アフ・１９８９（フォンデン・チル・フレメ・アフ・エクスペリメンテル・カンセアフォースクニング） uPAR binding site of domain 2 + 3 of uPAR and antibody
IT1271684B (en) * 1994-07-22 1997-06-04 Consiglio Nazionale Ricerche ANTISENSE OLIGONUCLEOTIDES COMPLEMENTARY TO THE MESSENGER RNA OF THE HUMAN UROKINASE RECEPTOR
US6277818B1 (en) 1998-10-29 2001-08-21 Angstrom Pharmaceuticals, Inc. Cyclic peptide ligands that target urokinase plasminogen activator receptor
US5942492A (en) 1996-11-12 1999-08-24 Angstrom Pharmaceuticals, Inc. Cyclic peptides that bind to urokinase-type plasminogen activator receptor
US5994309A (en) 1997-07-25 1999-11-30 Angstrom Pharmaceuticals, Inc. Anti-invasive and anti-angiogenic compositions and methods
CA2406882A1 (en) * 1999-10-01 2001-04-12 Angstrom Pharmaceuticals, Inc. Diagnostic probes and therapeutics targeting upa and upar
US6896870B1 (en) 1999-10-01 2005-05-24 Angstrom Pharmaceuticals, Inc. Diagnostic probes and therapeutics targeting uPA and uPAR
US6649597B1 (en) 2000-06-22 2003-11-18 The University Of Iowa Research Foundation Targeting vector to the urokinase plasminogen activator receptor
US7045283B2 (en) * 2000-10-18 2006-05-16 The Regents Of The University Of California Methods of high-throughput screening for internalizing antibodies
DE60219888T2 (en) * 2001-01-25 2008-01-17 Fondazione Centro San Raffaele Del Monte Tabor ANTIBODIES FOR MODULATING UPA / UPAR INTERACTION AND ITS USES
KR100871454B1 (en) 2001-05-21 2008-12-03 옴릭스 바이오파머슈티컬즈 에스. 에이. Removal of Plasmin (Ogen) from Protein Solution
DE10153601A1 (en) * 2001-11-02 2003-05-22 Paion Gmbh DSPA for the treatment of stroke
CA2517027A1 (en) 2002-02-25 2003-09-04 Vaxiion Therapeutics, Inc. Minicell compositions and methods
JP2004137151A (en) * 2002-10-15 2004-05-13 Keio Gijuku Brain tumor treatment and diagnostics
WO2005048822A2 (en) * 2003-11-18 2005-06-02 Attenuon Llc Antibodies and/or conjugates thereof which bind to the amino terminal fragment of urokinase, compositions and uses thereof
US7449196B2 (en) * 2004-07-09 2008-11-11 Robert Sabin Anti tumor compositions and methods of use
WO2006079929A2 (en) * 2005-01-31 2006-08-03 Fondazione Centro San Raffaele Del Monte Tabor Therapeutic peptides derived from urokinase plasminogen activator receptor
TW200813091A (en) 2006-04-10 2008-03-16 Amgen Fremont Inc Targeted binding agents directed to uPAR and uses thereof
US20080081051A1 (en) * 2006-09-28 2008-04-03 Robert Sabin Method of manufacturing anti-tumor and anti-viral compositions
AU2007300996B2 (en) * 2006-09-28 2013-10-31 Shimadzu Corporation Method for deparaffinization of paraffin-embedded specimen and method for analysis of paraffin-embedded specimen
JP2010512324A (en) * 2006-12-08 2010-04-22 アッテヌオン エル エル シー Urokinase-type plasminogen activator receptor epitope, monoclonal antibody derived therefrom and method of use thereof
US8815519B2 (en) * 2006-12-22 2014-08-26 Hvidovre Hospital Method for predicting cancer and other diseases
EP2126067B1 (en) * 2007-02-23 2014-07-02 Landing Biotech, Inc. Treating atherosclerosis
CA2681481A1 (en) * 2007-03-16 2008-09-25 Mount Sinai School Of Medicine Induction and/or maintenance of tumor dormancy by disruption of urokinase plasminogen activator receptor-integrin interaction
US9333280B2 (en) 2009-02-25 2016-05-10 Teleflex Medical Incorporated Stabilized enzyme compositions
WO2015048619A2 (en) * 2013-09-30 2015-04-02 Teleflex Medical Incorporated Stabilized enzyme compositions
JP7604376B2 (en) 2018-12-28 2024-12-23 バーテックス ファーマシューティカルズ インコーポレイテッド Modified urokinase-type plasminogen activator polypeptides and methods of use - Patents.com
US11613744B2 (en) 2018-12-28 2023-03-28 Vertex Pharmaceuticals Incorporated Modified urokinase-type plasminogen activator polypeptides and methods of use

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987000549A1 (en) * 1985-07-12 1987-01-29 Fonden Til Fremme Af Eksperimentel Cancerforskning Plasminogen activator inhibitor monoclonal antibodies, hybridomas, monoclonal antibody production and use of the antibodies for purification, removal, inhibition or assay of the inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4571421A (en) * 1979-11-05 1986-02-18 Genentech, Inc. Mammalian gene for microbial expression
DOP1982004086A (en) * 1981-08-27 1988-03-22 Lilly Co Eli PHARMACEUTICAL FORMULA INCLUDING HUMAN INSULIN AND HUMAN PROINSULIN
US4791068A (en) * 1984-06-22 1988-12-13 Scripps Clinic And Research Foundation Diagnostic assay for inhibitor of tissue-type and urokinase-type plasminogen activators
AU5770786A (en) * 1985-04-15 1986-11-05 Biotechnology Research Partners Limited Human anti-inflammatory phospholipase inhibitor protein
US5053386A (en) * 1987-07-24 1991-10-01 Tung Ta C Orally administrable anti-metastatic lectin compositions and methods
GB2246779B (en) * 1990-08-03 1994-08-17 Delta Biotechnology Ltd Tumour-associated protease inhibitors targeted to tumour cells
US5340833A (en) * 1992-05-01 1994-08-23 Eisai Co., Ltd. Urokinase inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987000549A1 (en) * 1985-07-12 1987-01-29 Fonden Til Fremme Af Eksperimentel Cancerforskning Plasminogen activator inhibitor monoclonal antibodies, hybridomas, monoclonal antibody production and use of the antibodies for purification, removal, inhibition or assay of the inhibitors

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
ASTEDT B ET AL: "RADIO IMMUNOASSAY OF URO KINASE FOR QUANTIFICATION OF PLASMINOGEN ACTIVATORS RELEASED IN OVARIAN TUMOR CULTURES", EUROPEAN JOURNAL OF CANCER, vol. 17, no. 2, 1981, pages 239 - 244, XP008025822, ISSN: 0014-2964 *
CUBELLIS M V ET AL: "RECEPTOR-MEDIATED INTERNALIZATION AND DEGRADATION OF UROKINASE IS CAUSED BY ITS SPECIFIC INHIBITOR PAI-1", EMBO JOURNAL, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 9, no. 4, 1990, pages 1079 - 1085, XP002027849, ISSN: 0261-4189 *
ELLIS V. ET AL: "Inhibition of receptor-bound urokinase by plasminogen-activator inhibitors", J BIOL CHEM, vol. 265, no. 17, 15 June 1990 (1990-06-15), pages 9904 - 9908, XP002273110 *
ELLIS, V. ET AL: "Plasminogen activation initiated by single chain urokinase-type plasminogen activator", J BIOL CHEM, vol. 264, no. 4, 5 February 1989 (1989-02-05), pages 2185 - 2188, XP001176828 *
NIEDBALA M J ET AL: "REGULATION BY EPIDERMAL GROWTH FACTOR OF HUMAN SQUAMOUS CELL CARCINOMA PLASMINOGEN ACTIVATOR-MEDIATED PROTEOLYSIS OF EXTRACELLULAR MATRIX", CANCER RESEARCH, vol. 49, no. 12, 1989, pages 3302 - 3309, XP008028623, ISSN: 0008-5472 *
ROLDAN A L ET AL: "CLONING AND EXPRESSION OF THE RECEPTOR FOR HUMAN UROKINASE PLASMINOGEN ACTIVATOR, A CENTRAL MOLECULE IN CELL SURFACE, PLASMIN DEPENDENT PROTEOLYSIS", EMBO JOURNAL, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 9, no. 2, 1 February 1990 (1990-02-01), pages 467 - 474, XP000086848, ISSN: 0261-4189 *
SCHUH T. ET AL: "Protease inhibitors prevent plasminogen mediated but not pemphigus vulgaris induced acantholysis in human epidermis.", BIOL CHEM, vol. 384, February 2003 (2003-02-01), pages 311 - 315, XP008025491 *
STEPHENS R. W. ET AL: "Activation of pro-urokinase and plasminogen on human sarcoma cells: a proteolytic system with surface bond reactants", J CELL BIOL., vol. 108, May 1989 (1989-05-01), pages 1987 - 1995, XP002264264 *

Also Published As

Publication number Publication date
CA2051676A1 (en) 1990-10-08
DE467932T1 (en) 1993-01-14
JP2002062295A (en) 2002-02-28
AU5528090A (en) 1990-11-05
EP1013285A2 (en) 2000-06-28
EP0467932A1 (en) 1992-01-29
WO1990012091A1 (en) 1990-10-18
DE69033653T2 (en) 2001-06-07
AU683951B2 (en) 1997-11-27
DK0467932T3 (en) 2001-02-12
DE69033653D1 (en) 2000-11-23
AU652917B2 (en) 1994-09-15
US6248712B1 (en) 2001-06-19
ATE197067T1 (en) 2000-11-15
EP0467932B1 (en) 2000-10-18
AU8046394A (en) 1995-04-13
JPH04506148A (en) 1992-10-29

Similar Documents

Publication Publication Date Title
EP1013285A3 (en) Urokinase-type plasminogen activator receptor
IL52124A (en) Tripeptide derivatives and method for the quantitative determination of plasminogen activators,inhibitors thereof and trypsin,trypsin inhibitors and trypsinogen in human and mammal body fluids and tissue extracts therewith
AU6806487A (en) Tissue plasminogen activator
AU633366B2 (en) Human tissue plasminogen activator-human plasminogen activator inhibitor complex immunoassay and kit therefor
IE892630L (en) Novel combination
AU589283B2 (en) Synergistic blood clot treatment composition comprising tissue plasminogen activator and a prostaglandin
IL91774A0 (en) Preparation of plasminogen activator expressed in prokaryotes
EP0339505A3 (en) Monoclonal antibodies to tissue plasminogen activator (t-pa) which prolong its functional half-life
NO168055C (en) PROCEDURE FOR MANUFACTURING HUMAN Tissue PLASMINOGEN ACTIVATOR AND UROKINASE TYPE PLASMINOGEN ACTIVATOR.
GB8901422D0 (en) New tissue plasminogen activator
GB8815245D0 (en) New tissue plasminogen activator
AU609337B2 (en) Tissue plasminogen activator (t-pa) muteins and processes for the preparation thereof
GB8826692D0 (en) Tissue plasminogen activator
GB8815247D0 (en) New tissue plasminogen activator
GB8815246D0 (en) New tissue plasminogen activator
EP0337817A3 (en) Plasminogen activator and thrombolytic agent
IE882534L (en) Peg complex of tissue plasminogen activator
IL86887A0 (en) Improved human tissue plasminogen activator and its use
IE883342L (en) Human tissue-type plasminogen activator variant
DK7491D0 (en) TISSUE PLASMINOGEN ACTIVATOR ANALOG
IL109760A0 (en) Modified human tissue-type plasminogen activator which retains its biological activity and is characterized by an increased in vivo hlaf-life
BR1100888A (en) Variants of tissue plasminogen activator, compositions and methods of using the same
IL109735A0 (en) Tissue plasminogen activator having zymonogenic or fibrin specific properties
GB9000629D0 (en) Tissue plasminogen activator
FI880891A7 (en) Composition of recombinant human tissue plasminogen activator.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AC Divisional application: reference to earlier application

Ref document number: 467932

Country of ref document: EP

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB IT LI LU NL SE

RIN1 Information on inventor provided before grant (corrected)

Inventor name: BEHRENDT, NIELS

Inventor name: SCHLEUNING, WOLF DIETER

Inventor name: APPELLA, ETTORE, C/O LAB. FOR CELL BIOLOGY

Inventor name: MASUCCI, MARIA TERESA, C/O EXPER. ONCOLOGY DEPT B

Inventor name: CUBELLIS, ANN LOURING, C/O DIP. DE CHEM ORG. E BI

Inventor name: ROLDAN, ANN LOURING

Inventor name: BLASI, FRANCESCO

Inventor name: DANO, KELD

RIN1 Information on inventor provided before grant (corrected)

Inventor name: BEHRENDT, NIELS

Inventor name: SCHLEUNING, WOLF DIETER

Inventor name: APPELLA, ETTORE, C/O LAB. FOR CELL BIOLOGY

Inventor name: MASUCCI, MARIA TERESA, C/O EXPER. ONCOLOGY DEPT B

Inventor name: CUBELLIS, MARIA VITTORIA, DIP. CHEM ORG. E BIO

Inventor name: ROLDAN, ANN LOURING

Inventor name: BLASI, FRANCESCO

Inventor name: DANO, KELD

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61K 38/49 A

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB IT LI LU NL SE

AKX Designation fees paid
REG Reference to a national code

Ref country code: DE

Ref legal event code: 8566

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20041120